Abstract
Background
Diagnosing a rare disease, such as amyotrophic lateral sclerosis, is a major challenge for physicians and patients. Despite detailed diagnostic criteria, this process often does not proceed as it should, exacerbating the problems of patients. In the following study, we show how the process, which in medical sciences has been called the “diagnostic odyssey”, proceeds and how it affects patients.
Materials and methods
Participants were recruited via a neurology clinic. Twenty-four patients with the diagnosed disease were interviewed using in-depth interviews and an author questionnaire: 9 females and 15 males ages ranging from 30–39 to 60–69.
Results
The median time from 1st symptoms to diagnosis was almost 12 months and mean almost 20 months (min. 3, max 106). Only 5 patients waited less than 6 months for being diagnosed. Over 80% of patients received an alternative diagnosis on the first attempt.
Conclusion
ALS is a fast-paced fatal disease, which requires immediate action to slow down the course of the disease and improve patients’ quality of life. However, in many cases, the disease is diagnosed too late. It also happens that a wrong diagnosis causes inaccurate treatment, which accelerates the development of ALS. For this reason, it is necessary to expand the clinical and communication competences of medical personnel already at the stage of medical studies. In addition, the diagnostic criteria should highlight the common problem with diagnosing ALS.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Amyotrophic lateral sclerosis (ALS) is a rare, incurable, and fatal neurodegenerative disease characterized by progressive muscular paralysis. This devastating disease occupies both central and peripheral motor neurons [1], rapidly bringing the patient to disability. Median survival amounts from 37 to 49 months [2]. The prevalence of ALS ranges from about 1/100,000 to even 8/100,000 in some regions [3, 4].
Due to the unfavorable nature of the diagnosis and ALS rapid course, prompt diagnosis and immediate treatment are of particular importance. Unfortunately, in many cases, this does not happen, and patients, instead of receiving quick help, wait for a diagnosis for months.
The study aimed to find out how the diagnosis of amyotrophic lateral sclerosis was carried out, including how long patients waited for the final diagnosis from the first symptoms they observed [5] and what diseases were diagnosed and even treated before the final diagnosis of ALS. Finally, we have also proposed recommendations for clinicians that can help improve the diagnostic process by taking into account patients’ perspectives.
Material and methods
The study approved by the Scientific Research Ethics Committee of the University of Warmia and Mazury in Olsztyn (decision no. 5/2018) was conducted using the PAPI method (pen-and-paper personal interviews) between February and June 2018. The study was based on the standardized original questionnaire containing 30 closed questions (demographic, diagnostic path, and opinions on the diagnosis), as well as 5 open questions (related to the patient’s experience in each area). The questionnaire translated from the Polish original is included in our previous paper describing breaking bad news [6]. The subjects of the study were patients of a private neurology clinic in Poland with diagnosed ALS based on El Escorial standards [7]. Important rules qualifying patients were the ability to communicate—even if with the help of a carer—and good mental health.
Thirty patients were qualified for the study, but ultimately results were collected from 26 people. Two cases were rejected due to the lack of full answers. Finally, 24 cases were used in the analysis which is a significant outcome given the rarity of the disease.
The obtained research group (Table 1) was demographically non-homogeneous: age was spread over 3 cohorts: 40–49 (33.3%), 50–59 (37.5%), and 60–69 years (25%). The distribution of sex (15 males and 9 females) corresponds to the distribution occurring in ALS and is characterized by the predominance of men with a 2:1 male-to-female gender ratio [8, 9]. The distribution of the sample around the “place of residence” variable was also relatively large, with a small advantage of the big city (over 250 t.) Respondents came also from different regions of Poland. The place of diagnosis is also varied as shown in Fig. 1.
Results
The median time from 1st symptoms to diagnosis was 12 months, and the medium time was 19.75 months (min 3, max 106, IQR: 15, Table 2). Only 5 patients waited less than 6 months for being diagnosed (Fig. 2). The largest value (106 months) refers to a patient with a chronic form of ALS and has ignored the symptoms himself. However, the remaining values were patients who received a late diagnosis due to a process called “diagnostic odyssey” which means that patients were diagnosed and treated for a long time by different specialists in different centers, unable to obtain a reliable diagnosis [5, 10].
One of the variables that had a significant impact on the prolonged time of diagnosis was the type of onset of ALS (p = 0.032) and patients with limb onset waited longer for diagnosis. Among the demographic factors that statistically significantly affected the length of diagnosis (delayed diagnosis) in the study group were male gender (p = 0.034) and higher education (p = 0.000). In the case of the group we analyzed, age had no significant effect. It seems, however, that this study group is too small and too little diversified, especially in terms of education to allow a broader conclusion in terms of demography.
Most of the patients (83%) received an alternative diagnosis after the first symptoms (Fig. 3, Table 2). Before a proper diagnosis, most of them were diagnosed with Lyme disease (n = 7), neurosurgical diseases (spinal injury, etc., n = 4), and mental disorders (neurosis, n = 2). Other diseases diagnosed were autoimmune, myasthenia gravis, cardiac, Parkinson’s, vocal cords disease, and in two cases “other problems”—overall weakness and “something serious”. ALS as the first diagnosis was indicated by 4 patients. Moreover, 8 patients (33%) admitted that they diagnosed themselves before visiting a doctor. Despite this, the diagnosis process was often carried out by the doctor without taking into account patients’ self-diagnosis.
It also happened that the 2nd or even the 3rd diagnosis was made incorrectly before the final diagnosis was made or the diagnosis of ALS was changed to a different health problem (Table 3).
The result of an incorrect diagnosis was another observed problem: over 41% (10 patients) of patients were treated for diseases they did not have, including antibiotic therapies for Lyme disease, medicines for myasthenia, and psychotherapy. As the respondents emphasized, the treatment only slowed the treatment of ALS and even led to a significant deterioration of health (Table 3).
Discussion
ALS is a rapidly progressing disease, and because of that, patients often indicated that they would like to learn about it as possible, even at the first suspicions by the doctor [6]. This would allow them to take immediate action that may delay the disease’s progression.
However, from a clinical point of view, the process of investigation from suspicion to diagnosis in medicine always requires diligence and entails liability for the consequences of an incorrect diagnosis. It includes history taking, physical examination, additional tests, and often consultations. In the case of chronic and rare diseases, the non-simultaneous appearance of symptoms and their potential sequence may be crucial for the time from their onset to the correct diagnosis. Also, the neurophysiological signs in EMG and their comparison to the diagnostic criteria of ALS are very important to diagnosis and level of evidence [11, 12]. However, this can be confusing as ALS is a disease with symptoms that connect with many different health problems, especially Lyme disease, neuropathy, myasthenia gravis, neurosis, and spine injuries [13].
On top of that, there is also the perspective of a doctor—a person who is the messenger of an unfavorable diagnosis. Information about diseases with a poor prognosis and without the prospect of effective treatment is provided to patients with extreme caution—usually after thorough verification and obtaining certainty about its truthfulness. Often, the mere suspicion of a disease by a doctor raises so much concern that diagnosis is made under confidential conditions until the most accurate results and verification are obtained. These practices are designed to protect the patient from exposure to unjustified fears for health and life—but are they ethical and effective [14]? As we have already indicated, most of the patients we surveyed would like to hear a diagnosis even at the first suspicion.
However, even raising suspicion can be difficult. In ALS, neurological symptoms start slowly, with no pain symptoms, which often put anxiety to sleep. The first to appear are motor deficits, muscle atrophy, or speech and swallowing disorders. This leads to starting diagnostics with potentially different specialists: neurologists, neurosurgeons, phoniatrist, and speech therapists. This is a potential factor that extends the patient’s journey to a neurological or neuromuscular clinic [5, 15].
Conclusions
In our study, as well as based on the literature, it can be concluded that the process of the diagnostic odyssey in ALS, but also in other chronic and rare diseases, is a reality faced by both clinicians and their patients on a daily basis. The causes of this problem lie both in the sphere of the patient’s perception, the knowledge and diagnostic abilities of experts, and the way the healthcare system functions.
Factors that may delay the diagnosis in ALS include above all:
-
Time from 1st symptoms to reasonable suspicion and referral for neurophysiological diagnostics
-
Waiting time for tests and results
-
Waiting time for follow-up visits
-
Differential diagnosis period with low confirmation criteria (waiting for the fulfillment of El Escorial/Awai/Gold Coast diagnostic criteria)
-
Delay by diagnosing and treating the “dead ends” of differential tests
-
Waiting time to reference to diagnostic centers
-
The need for the patient to verify the truth of “bad news” with other specialists
How can this problem be addressed? The basic answer is education at the stage of medical studies, which should be focused on careful medical history taking [16], also from the side of medical communication, self-awareness of one’s limitations and routine [17]. In addition, the diagnostic criteria should highlight the common problem with diagnosing ALS. The diagnostic criteria of ALS evolve from useful mostly in experimental trials to more helpful for clinical practice [7]. Those changes and of course wide knowledge of current criteria by neurologists may minimize the delay of diagnosis.
Data availability
All raw data in anonymized form are available upon notification to the corresponding author.
References
Stifani N (2014) Motor neurons and the generation of spinal motor neuron diversity. Front Cell Neurosci 8:293
Jablecki CK, Berry C, Leach J (1989) Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 12:833–841
Chio A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130
Rosenbohm A, Liu M, Nagel G et al (2018) Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol 265:774–782
Black N, Martineau F, Manacorda T (2015) Diagnostic odyssey for rare diseases: exploration of potential indicators. London: Policy Innovation Research Unit, LSHTM
Maksymowicz S, Libura M, Malarkiewicz P (2022) Overcoming therapeutic nihilism. Breaking bad news of amyotrophic lateral sclerosis-a patient-centred perspective in rare diseases. Neurol Sci. https://doi.org/10.1007/s10072-022-05931-1
Johnsen B (2020) Diagnostic criteria for amyotrophic lateral sclerosis from El Escorial to Gold Coast. Clin Neurophysiol 131(8):1962–1963. https://doi.org/10.1016/j.clinph.2020.04.012
Logroscino G, Traynor BJ, Hardiman O et al (2008) Eurals (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11
Logroscino G, Traynor BJ, Hardiman O et al (2010) Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81(4):385–390. https://doi.org/10.1136/jnnp.2009.183525
Thevenon J, Duffourd Y, Masurel-Paulet A et al (2016) Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin Genet 89(6):700–707. https://doi.org/10.1111/cge.12732
Lenglet T, Camdessanché JP (2017) Amyotrophic lateral sclerosis or not: Keys for the diagnosis. Rev Neurol (Paris) 173(5):280–287. https://doi.org/10.1016/j.neurol.2017.04.003
Swash M (2000) Shortening the time to diagnosis in ALS: the role of electrodiagnostic studies. Amyotroph Lateral Scler Other Motor Neuron Disord 1(Suppl 1):S67-72
Paganoni S, Macklin EA, Lee A et al (2014) Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener 15(5–6):453–456. https://doi.org/10.3109/21678421.2014.903974
Lemus-Riscanevo P, Carreño-Moreno S, Arias-Rojas M (2019) Conspiracy of silence in palliative care: a concept analysis. Indian J Palliat Care 25(1):24–29. https://doi.org/10.4103/IJPC.IJPC_183_18
Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M (2014) Delayed diagnosis in ALS: the problem continues. J Neurol Sci 343(1–2):173–175. https://doi.org/10.1016/j.jns.2014.06.003
Maksymowicz S, Kukołowicz P, Siwek T, Rakowska A (2020) Validation of the revised amyotrophic lateral sclerosis functional rating scale in Poland and its reliability in conditions of the medical experiment. Neurol Sci. https://doi.org/10.1007/s10072-020-04565-5
Munoz Sastre MT, Sorum PC, Mullet E (2011) Breaking bad news: the patient’s viewpoint. Health Commun 26(7):649–655. https://doi.org/10.1080/10410236.2011.561919
Author information
Authors and Affiliations
Contributions
S.M.: study design, data collection, data analysis, manuscript preparation.
T.S.: data analysis, manuscript preparation.
Corresponding author
Ethics declarations
Ethical approval
The study was approved by The Scientific Research Ethics Committee of University of Warmia and Mazury in Olsztyn, Poland, no. 5/2018.
Informed consent
The patients were informed about the objectives and method of the study and consented to the use of their statements and anonymized data for scientific purposes and publication.
Consent to participate and publication
The patients were informed about the objectives and method of the study and consented to the use of their statements and anonymized data for scientific purposes and publication.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Maksymowicz, S., Siwek, T. Diagnostic odyssey in amyotrophic lateral sclerosis: diagnostic criteria and reality. Neurol Sci 45, 191–196 (2024). https://doi.org/10.1007/s10072-023-06997-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-023-06997-1